文章：

选择性与非选择性β受体阻滞剂对墨西哥乳腺癌患者骨密度的影响

Effects of Selective and Nonselective Beta Blockers on Bone Mineral Density in Mexican Patients with Breast Cancer

原文发布日期：20 August 2024

DOI: 10.3390/cancers16162891

类型: Article

开放获取: 是

英文摘要：

Breast cancer (BCa) is related to chronic stress and can reduce the bone mineral density (BMD) through neurochemicals related to beta-adrenergic receptor (ADRB) 1 and 2. Selective beta blockers (sBBs) and nonselective beta blockers (nsBBs) are used to treat systemic arterial hypertension (SAH) and may have osteoprotective effects, as they inhibit ADRBs. To evaluate the effects of sBBs and nsBBs on the BMD of Mexican patients with BCa. A retrospective study was conducted. We included 191 Mexican women with BCa without SAH and with SAH treated with nsBBs, sBBs, and diuretics. BMD was evaluated using a bone density scan (DEX scan). A greater average BMD (p< 0.05) was observed in patients with prior treatment with both nsBBs and sBBs (0.54 ± 0.94 and −0.44 ± 1.22, respectively) compared to patients treated with diuretics or without SAH (−1.73 ± 0.83 and −1.22 ± 0.98, respectively). Regarding the diagnosis of osteoporosis/osteopenia, no cases were observed in patients treated with nsBBs, whereas 5.6% of the patients treated with sBBs presented osteopenia. A total of 23.1% and 10.6% patients managed with diuretics or without treatment presented with osteoporosis and 61.5% and 48% patients managed with loop diuretics and without treatment presented with osteopenia, respectively (p< 0.05). Treatment with nsBBs is a promising option for the prevention and management of osteoporosis/osteopenia in Mexican patients with BCa; however, further prospective studies are needed.

摘要翻译： 

乳腺癌与慢性应激相关，可通过β-肾上腺素能受体1和2相关的神经化学物质降低骨密度。选择性β受体阻滞剂和非选择性β受体阻滞剂常用于治疗系统性动脉高血压，因其能抑制β-肾上腺素能受体，可能具有骨保护作用。本研究旨在评估这两类药物对墨西哥乳腺癌患者骨密度的影响。我们开展了一项回顾性研究，纳入191例墨西哥女性乳腺癌患者，包括无高血压者、接受非选择性β受体阻滞剂治疗的高血压患者、接受选择性β受体阻滞剂治疗的高血压患者以及接受利尿剂治疗的高血压患者。通过骨密度扫描评估骨密度。结果显示：接受非选择性β受体阻滞剂与选择性β受体阻滞剂治疗的患者平均骨密度显著更高（分别为0.54±0.94和-0.44±1.22），而利尿剂治疗组与无高血压组的骨密度较低（分别为-1.73±0.83和-1.22±0.98），组间差异具有统计学意义（p<0.05）。在骨质疏松/骨量减少诊断方面：非选择性β受体阻滞剂治疗组未发现相关病例；选择性β受体阻滞剂治疗组骨量减少发生率为5.6%；利尿剂治疗组骨质疏松发生率为23.1%，骨量减少发生率为61.5%；无高血压组骨质疏松发生率为10.6%，骨量减少发生率为48%，组间差异显著（p<0.05）。研究表明，非选择性β受体阻滞剂治疗可能是预防和管理墨西哥乳腺癌患者骨质疏松/骨量减少的有效方案，但尚需进一步开展前瞻性研究验证。

原文链接：

Effects of Selective and Nonselective Beta Blockers on Bone Mineral Density in Mexican Patients with Breast Cancer